#151621

Anti-MMP9 [2C3]

Please Enter Your Email ID
Email ID

Cat. #151621

Anti-MMP9 [2C3]

Cat. #: 151621

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Human matrix metalloproteinase 9 (MMP-9)

Class: Monoclonal

Application: IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-MMP9 [2C3]
  • Research fields: Cancer;Cell biology;Genetics;Tissue-specific biology
  • Clone: 2C3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB
  • Description: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.
  • Immunogen: Ovalbumin-conjugated synthetic peptide; KLGLGADVAQVT
  • Isotype: IgG1 kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: IHC: formalin-fixed, paraffin-embedded lung containing intra-alveolar macrophage. Western Blot: rhMMP-9, 400 ng per lane

Target Details

  • Target: Human matrix metalloproteinase 9 (MMP-9)
  • Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded lung containing intra-alveolar macrophage. Western Blot: rhMMP-9, 400 ng per lane
  • Target background: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of MMP9 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.

Applications

  • Application: IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Sreekanth et al. 2011. Oncogene. 30(28):3139-52. PMID: 21317920.
  • Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
  • Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
  • The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
  • Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
  • Profiling markers of prognosis in colorectal cancer.
  • Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
  • Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
  • Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
  • Matrix metalloproteinases and their inhibitors in gastric cancer.
  • Duncan et al. 1998. Eur J Biochem. 258(1):37-43. PMID: 9851689.
  • Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.
  • Murray et al. 1998. J Pathol. 185(3):256-61. PMID: 9771478.
  • Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.